 It is sold as landiolol hydrochloride.Based on its positive benefit risk profile, landiolol has been granted the marketing authorization and introduced to the European markets under the brand names "Rapibloc", "Raploc", "Runrapiq", "Landibloc" mid 2016 (in 2 formulations of 300 mg vial and 20 mg ampoule).Landiolol is available in Japan under the brand names "Onoact" (50 mg) and "Corbeta" (12.5 mg for Improvement of Image Quality in Coronary CT Angiography).